Introduction: Infantile spasms (IS) is a rare and devastating form of early childhood epilepsy. Two drugs are approved in the United States for treatment of IS, H.P. Acthar Gel (repository corticotropin injection, RCI) and Sabril (vigabatrin). Given real-world variation in treatment of patients with IS, this study characterized treatment patterns with IS medications and determined all-cause health care resource utilization (HCRU) during the 90 days before initiating therapy with RCI in patients with IS.

Materials And Methods: Truven Health MarketScan Research Databases were used to identify commercially insured US patients <2 years of age at RCI initiation with an IS diagnosis, per label use, from 1/1/07 to 12/31/15; presence of an electroencephalogram following diagnosis was required to assure diagnosis. Diagnosis codes and dispensed IS treatments of interest (drug classes including corticosteroids, vigabatrin, and other antiepileptic drugs [AEDs] excluding vigabatrin) before RCI initiation were evaluated.

Results: The 5 most common diagnoses other than IS observed in the study cohort (n=422) were "other convulsions," "acute upper respiratory infection," "esophageal reflux," "epilepsy, unspecified," and "abnormal involuntary muscle movements." Among the study cohort, 51.7% received RCI first; 38.9% received 1 drug class and 9.5% received >1 drug class before RCI initiation. Other AEDs were dispensed most often, either alone (31.3%) or with other drug classes (9.3%). Mean HCRU included 11.8 all-cause outpatient visits and 4.5 medications dispensed. Patients who received RCI or corticosteroids as their initial IS treatment had the lowest and second-lowest HCRU.

Conclusion: In the 90 days before initiating RCI, patients with IS received multiple diagnoses and treatments, characterized by frequent HCRU. Use of RCI first (no prior IS medications) and AEDs first were associated with the lowest and highest HCRU, respectively, across all categories (all-cause outpatient visits, emergency department visits, hospital admissions, prescription medications).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997416PMC
http://dx.doi.org/10.2147/PHMT.S222010DOI Listing

Publication Analysis

Top Keywords

repository corticotropin
8
corticotropin injection
8
infantile spasms
8
days initiating
8
rci patients
8
all-cause outpatient
8
outpatient visits
8
patients received
8
patients
6
rci
6

Similar Publications

Cutaneous sarcoidosis: clinical and pathologic features, molecular pathogenesis, and treatment.

Clin Dermatol

December 2024

Department of Dermatology, Yale School of Medicine, 333 Cedar St, LMP 5040, PO Box 208059, New Haven, Connecticut, 06510, United States. Electronic address:

Sarcoidosis is a multisystem inflammatory disorder that most commonly affects the lungs, lymphatic system, eyes, and skin. Cutaneous involvement is present in approximately 20-30% of patients. Prednisone and corticotropin repositories are the only FDA-approved therapies for sarcoidosis.

View Article and Find Full Text PDF

The goal of this market research study was to determine the usability of a single-dose prefilled injector (SelfJect™) for administration of Acthar Gel (manufactured by Mallinckrodt Pharmaceuticals, UK) in patients with inflammatory diseases by obtaining feedback from patient and practitioner user groups in the US. Patients and healthcare professionals (HCPs) representing relevant therapeutic areas were enrolled in the study between February and March 2021. SelfJect was mailed to patients and HCPs prior to 90-min virtual video-recorded focus group sessions and 60-min 1:1 virtual interviews, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • Acthar Gel is used to treat various inflammatory disorders and is usually administered with a syringe, but the SelfJect™ prefilled injector aims to make this process easier for subcutaneous delivery.
  • The review focused on factors like skin depth and needle gauge to assess SelfJect's suitability for children, noting that infants may be at risk of inadvertent intramuscular injections, but these pose no additional risk due to the drug's effectiveness in either method.
  • While SelfJect is generally safe for children and adolescents under supervision, it is recommended that an adult administer the device to ensure proper use and avoid potential adverse effects at the injection site.
View Article and Find Full Text PDF

Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.

J Ophthalmic Inflamm Infect

October 2024

Department of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.

Background: Repository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis.

Main Body: Medical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!